Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02635035 · ClinicalTrials.gov registry record · Phase 2

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

A Phase 2 study of Attention Deficit Hyperactivity Disorder and Attention Deficit Disorder, sponsored by NYU Langone Health.

Completed
Registry status
Phase 2
Development phase
38
Enrollment target
2
Study locations

NCT02635035 is a Phase 2 study of Attention Deficit Hyperactivity Disorder and Attention Deficit Disorder that has completed, run by NYU Langone Health. The registered enrollment target is 38 participants, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02635035, a Phase 2 study of Attention Deficit Hyperactivity Disorder and Attention Deficit Disorder, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
Phase 2
Development phase
38 participants
Enrollment target
2
Study locations

Study Summary

The primary purpose of this study is to test the efficacy of Lisdexamfetamine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT). This is a placebo controlled, cross-over clinical trial of oral Lisdexamfetamine Dimesylate 30-70mg/day in adults with attention-deficit hyper-activity disorder and Sluggish Cognitive Tempo (ACT). Patients will be assigned either LDX/Placebo for 10 weeks with a two week placebo washout period.

Conditions Studied

Attention Deficit Hyperactivity Disorder Attention Deficit Disorder

Interventions

  • DRUG Placebo
  • DRUG Lisdexamfetamine

Study Locations (2)

New York

  • Mount Sinai School of Medicine - New York
  • New York University School of Medicine - New York

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2015-11
Est. Completion 2019-01-09
Phase Phase 2

Sponsor

NYU Langone Health

1,164 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02635035

The ClinicalTrials.gov registry entry for NCT02635035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (82% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02635035 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02635035 about?

NCT02635035 is a clinical study titled "Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT". The primary purpose of this study is to test the efficacy of Lisdexamfetamine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT). This is a placebo controlled, cross-over clinical trial of oral Lisdexamfetamine Dimesylate 30-70mg/day in adults with atte...

What is the current status of trial NCT02635035?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2015-11. Estimated completion is 2019-01-09.

What conditions does trial NCT02635035 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder.

What interventions are being tested in trial NCT02635035?

The interventions under investigation include: Placebo (DRUG), Lisdexamfetamine (DRUG).

Who is sponsoring clinical trial NCT02635035?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02635035 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Attention Deficit Hyperactivity Disorder

All registered trials for this condition

Attention Deficit Disorder

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.